Get in on AlloVir Inc.’s (ALVR) buy-in window today!

AlloVir Inc. (NASDAQ: ALVR) stock jumped 13.96% on Friday to $8.00 against a previous-day closing price of $7.02. With 1.21 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.49 million shares. The 52-week range on ALVR shows that it touched its highest point at $26.41 and its lowest point at $3.17 during that stretch. It currently has a 1-year price target of $28.33.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALVR was up-trending over the past week, with a rise of 44.67%, but this was up by 67.71% over a month. Three-month performance surged to 95.12% while six-month performance fell -1.72%. The stock lost -62.67% in the past year, while it has lost -38.18% so far this year. A look at the trailing 12-month EPS for ALVR yields -2.93 with Next year EPS estimates of -2.67. For the next quarter, that number is -0.67. This implies an EPS growth rate of -143.10% for this year and -4.90% for next year.

Float and Shares Shorts:

At present, 64.47 million ALVR shares are outstanding with a float of 57.36 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.76 million, which was 7.27% higher than short shares on Jun 14, 2022. In addition to Mr. David L. Hallal as the firm’s Exec. Chairman, Dr. Diana M. Brainard M.D. serves as its CEO & Director.

Institutional Ownership:

Through their ownership of 29.77% of ALVR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 47.07% of ALVR, in contrast to 24.09% held by mutual funds. Shares owned by individuals account for 17.67%. As the largest shareholder in ALVR with 12.13% of the stake, Fidelity Management & Research Co holds 7,936,530 shares worth 7,936,530. A second-largest stockholder of ALVR, The Vanguard Group, Inc., holds 2,601,681 shares, controlling over 3.98% of the firm’s shares. Invus Public Equities Advisors LL is the third largest shareholder in ALVR, holding 2,323,371 shares or 3.55% stake. With a 3.48% stake in ALVR, the Fidelity Growth Company Fund is the largest stakeholder. A total of 2,278,383 shares are owned by the mutual fund manager. The Fidelity Select Port. – Biotechno, which owns about 1.44% of ALVR stock, is the second-largest Mutual Fund holder. It holds 944,668 shares valued at 3.68 million. Vanguard Total Stock Market Index holds 1.30% of the stake in ALVR, owning 851,259 shares worth 3.32 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALVR since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALVR analysts setting a high price target of $32.00 and a low target of $23.00, the average target price over the next 12 months is $27.50. Based on these targets, ALVR could surge 300.0% to reach the target high and rise by 187.5% to reach the target low. Reaching the average price target will result in a growth of 243.75% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ALVR will report FY 2022 earnings on 02/09/2023. Analysts have provided yearly estimates in a range of -$2.02 being high and -$2.52 being low. For ALVR, this leads to a yearly average estimate of -$2.29. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. AlloVir Inc. surprised analysts by $0.01 when it reported -$0.69 EPS against a consensus estimate of -$0.70. The surprise factor in the prior quarter was $0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.47 and the low estimate is -$0.63. The average estimate for the next quarter is thus -$0.55.

Summary of Insider Activity:

Insiders traded ALVR stock several times over the past three months with 5 Buys and 5 Sells. In these transactions, 100,625 shares were bought while 46,533 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has risen to 35 over the past year. The total number of shares bought during that period was 512,835 while 183,250 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *